SCHEMBL10124938

SCHEMBL10124938

O=C(NCCC(F)(F)F)c1ccc(-c2ccnc3[nH]ccc23)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK1 Q96PY6 5/20 0.77
IKBKB O14920 5/20 0.59
CHUK O15111 5/20 0.59
ROCK1 Q13464 3/20 0.50
DAPK3 O43293 2/20 0.50
JAK2 O60674 2/20 0.50
PAK4 O96013 2/20 0.50
CSF1R P07333 2/20 0.50
RET P07949 2/20 0.50
LTK P29376 2/20 0.50
KDR P35968 2/20 0.50
MAP2K2 P36507 2/20 0.50
MAPK8 P45983 2/20 0.50
CLK2 P49760 2/20 0.50
RPS6KA3 P51812 2/20 0.50
JAK3 P52333 2/20 0.50
CDK5 Q00535 2/20 0.50
MAP2K1 Q02750 2/20 0.50
MST1R Q04912 2/20 0.50
PTK2 Q05397 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10124944 0.88 NEK1 (0.72) NEK1IKBKBCHUKROCK1DAPK3
SCHEMBL10125151 0.88 PRKCI (0.61) NEK1IKBKBCHUKROCK1DAPK3
SCHEMBL10125090 0.85 NEK1 (0.82) NEK1IKBKBCHUKROCK1DAPK3
SCHEMBL14494460 0.84 NEK1 (0.54) NEK1IKBKBCHUKROCK1DAPK3
SCHEMBL4793711 0.82 NEK1 (0.77) NEK1IKBKBCHUKROCK1DAPK3
SCHEMBL4871172 0.82 NEK1 (0.77) NEK1IKBKBCHUKMAPK8CIT
SCHEMBL4790856 0.81 NEK1 (0.72) NEK1IKBKBCHUKCIT
SCHEMBL12346406 0.81 NUDT1 (0.60) NEK1IKBKBCHUKROCK1DAPK3
SCHEMBL858398 0.79 NEK1 (0.72) NEK1IKBKBCHUKCIT
SCHEMBL4793417 0.79 NEK1 (0.68) NEK1IKBKBCHUKROCK1DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921376-B2 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-30 US disclosed
US-8921376-B2 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-30 US disclosed
EP-1881983-B1 PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMA (US) 2012-01-11 EP disclosed
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-06-14 US disclosed
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase JAK2, JAK1, JAK3 NEK1 668/4885IKBKB 779/4885CHUK 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.